Safety of rosuvastatin

American Journal of Cardiology

Volumn 94, Issue 7, 2004, Pages 882-888

  Shepherd, James ^a,e   Hunninghake, Donald B ^b   Stein, Evan A ^c   Kastelein, John J P ^d   Harris, Susan ^b   Pears, John ^b   Hutchinson, Howard G ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c Pharmaceutical Product Development   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATIGUE; FEMALE; HEADACHE; HEALTH PROGRAM; HUMAN; INFORMATION PROCESSING; KIDNEY DISEASE; MALE; MEDICAL ASSESSMENT; MEDICAL EXAMINATION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; OPHTHALMOLOGY; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PROTEINURIA; RHABDOMYOLYSIS; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CHILD; CHOLESTEROL, LDL; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY; LIVER; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PROTEINURIA; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 5344244695     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.06.049     Document Type: Article

References (27)

1. R.C. Pasternak, S.C. Smith Jr, C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, C. Lenfant American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute ACC/AHA/NHLBI clinical advisory on the use and safety of statins J Am Coll Cardiol 40 2002 567 572
2. J.A. Staffa, J. Chang, L. Green Cerivastatin and reports of fatal rhabdomyolysis Correspondence N Engl J Med 346 2002 539 540
3. J.L. Beaumont, L.A. Carlson, G.R. Cooper, Z. Fejfar, D.S. Fredrickson, T. Strasser Classification of hyperlipidaemia and hyperlipoproteinaemias Bull World Health Organ 43 1970 891 915
4. D.R. Illingworth, J.R. Crouse III, D.B. Hunninghake, M.H. Davidson, I.D. Escobar, A.F. Stalenhoef, G. Paragh, P.T. Ma, M. Liu, M.R Melino Simvastatin Atorvastatin HDL Study Group A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial Curr Med Res Opin 17 2001 43 50
5. W. Insull Jr, J. Isaacsohn, P. Kwiterovich, P. Ra, R. Brazg, C. Dujovne, M. Shan, E. Shugrue-Crowley, S. Ripa, R. Tota Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial J Int Med Res 28 2000 47 68
6. COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms 4th Ed. 1993 Food and Drug Administration, US Department of Health and Human Services Washington, DC
7. A.G. Olsson, H. Istad, O. Luurila, L. Ose, S. Stender, J. Tuomilehto, O. Wiklund, H. Southworth, J. Pears, J.W. Wilpshaar for the Rosuvastatin Investigators Group Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia Am Heart J 144 2002 1044 1051
8. G.L. Myers, G.R. Cooper, C.L. Winn, S.J. Smith The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements Clin Lab Med 9 1989 105 135
9. D.W. Cockcroft, M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
10. F. Fodili, E.F.H. van Bommel Severe rhabdomyolysis and acute renal failure following recent coxsackie B virus infection Neth J Med 61 2003 177 179
11. D.G. Vidt, M.D. Cressman, S. Harris, J.S. Pears, H.G. Hutchinson Rosuvastatin-induced arrest in progression of renal disease Cardiology 102 2004 52 60
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
13. G. De Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, J. Dallongeville, S. Ebrahim, O. Faergeman, I. Graham, G. Mancia Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Eur Heart J 24 2003 1601 1610
14. R.H. Knopp Drug treatment of lipid disorders N Engl J Med 341 1999 498 511
15. D.M. Black, R.G. Bakker-Arkema, J.W. Nawrocki An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor Arch Intern Med 158 1998 577 584
16. C.B. Newman, G. Palmer, H. Silbershatz, M. Szarek Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients Am J Cardiol 92 2003 670 676
17. J.A. Farmer, G. Torre-Amione Comparative tolerability of the HMG-CoA reductase inhibitors Drug Saf 23 2000 197 213
18. M.H. Davidson Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust Drugs 61 2001 197 206
19. D.M. Black A general assessment of the safety of HMG CoA reductase inhibitors (statins) Curr Atheroscler Rep 4 2002 34 41
20. R.G. Bakker-Arkema, J.W. Nawrocki, D.M. Black Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Atherosclerosis 149 2000 123 129
21. P.D. Thompson, P. Clarkson, R.H. Karas Statin-associated myopathy JAMA 289 2003 1681 1690
22. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, E. Miller, V.A. Cain, J.W. Blasetto for the STELLAR Study Group Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial) Am J Cardiol 92 2003 152 160
23. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, Brunskill NJ. Inhibitors of HMG-CoA reductase reduce receptormediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004; in press.
24. Verhulst A, D'haese PC, De Broe ME. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004; in press.
25. J.M. McKenney, P.H. Jones, M.A. Adamczyk, V.A. Cain, B.S. Bryzinski, J.W. Blasetto Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial Curr Med Res Opin 19 2003 689 698
26. A.G. Olsson, F. McTaggart, A. Raza Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor Cardiovasc Drug Rev 20 2003 303 328
27. H. Schuster Rosuvastatin - a highly effective new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients Cardiology 99 2003 126 139